3.6 Safety outcomes
Bleeding complications occurred in 11.7% (n= 54) of all patients (table 4). Patients who had a bleeding at admission were more likely to be those who were already using a combined antithrombotic therapy prior to admission, whereas bleeding during hospitalisation was more likely to occur among patients who started the combined antithrombotic therapy during hospitalisation. Although the total of
patients are small per subgroup, the overall bleeding rate seems to be the highest in the subgroup of patients who were using TAT prior to hospitalisation.
The overall rate of thromboembolism in this study population was 5.4% (n=25) (table 4). This rate seems to be higher among patients at admission who therefore initiated a combined antithrombotic therapy during hospitalisation. However, two patients (2.1%) still had a thromboembolism at admission despite that DAT was initiated prior to hospitalization. A thromboembolism during hospitalization was seen in 1.3% (n= 6) of all patients and these patients all had initiated their combined therapy (DAT) after the thromboembolism.
The overall mortality rate was 4.3% (table 4).